Hori Takeshi, Ikehara Teruyuki, Takatsuka Satoshi, Fukuoka Tatsunari, Tendou Masanari, Tezuka Kenji, Dan Nobuhiro, Nishino Hiroji, Hirakawa Kosei
Department of Surgery, Kashiwara Municipal Hospital.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2309-11.
A 61-year-old man with esophagus invasive advanced gastric cancer and peritoneum dissemination underwent three courses of S-1/CDDP/Lentinan (LNT) combination neoadjuvant chemotherapies (T3N1P1H0, Stage IV) (It is S-1 80 mg/m2,CDDP 15 mg/m2 and LNT 2 mg/body twice/week for two weeks) since down staging was obtained. We performed the surgery of total gastrectomy, splenectomy, D2 lymph node dissection, and Roux-en Y reconstruction in March 2008. With the surgical examination, there was no ascites and peritoneal dissemination. Although there was serious infiltration, we were able to remove it. In the histopathological effect judgment, it was Grade 1b. We changed the therapy to S-1 alone after the same chemotherapy for six months. One year after the operation, he is still alive one year after the surgery.
一名61岁患有食管浸润性进展期胃癌伴腹膜转移的男性患者，自获得降期后接受了三个疗程的S-1/顺铂/香菇多糖（LNT）联合新辅助化疗（T3N1P1H0，IV期）（即S-1 80mg/m²、顺铂15mg/m²、LNT 2mg/体，每周两次，共两周）。2008年3月，我们为其实施了全胃切除术、脾切除术、D2淋巴结清扫术及Roux-en Y重建术。手术探查时，未见腹水及腹膜转移。尽管存在严重浸润，但我们仍成功将其切除。在组织病理学疗效判断中，为1b级。相同化疗6个月后，我们将治疗方案改为单纯S-1。术后一年，患者术后存活至今已一年。
